Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SBR759 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 1g bid |
| 2 | ACTIVE_COMPARATOR | 0.8 g tid |
| 3 | EXPERIMENTAL | 1.5 g tid |
| 4 | ACTIVE_COMPARATOR | 1.6 g tid |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| 7 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SBR759 | DRUG | 1g tid |
| Sevelamer HCl | DRUG | 1.6 g tid |
Inclusion criteria * Men or women of at least 18 years old or 20 years old in Japan. * Stable maintenance of hemodialysis 3 times per week. * Controlled serum phosphate if under phosphate-binder therapy. * Serum phosphate level \> 6.0 mg/dL (\> 1.9 mmol/L) prior to study treatment initiation. Excl...
Top 20 of 28 competitors
SBR759 is an investigational small molecule being developed for hyperphosphatemia in patients with chronic kidney disease on 3x/week replacement therapy, and for chronic kidney disease. It is designed to lower serum phosphate levels in patients on hemodialysis.
SBR759 is being developed by Novartis AG, traded on the New York Stock Exchange under the ticker NVS. The company has sponsored clinical trials evaluating the drug in chronic kidney disease patients with hyperphosphatemia.
SBR759 is in Phase 2 clinical development. Two Phase 2 trials have been completed, along with one Phase 1 trial. The drug is investigational and has not been approved by regulatory authorities.
SBR759 has completed two Phase 2 trials: NCT00704483 in 321 patients across multiple countries, and NCT00704678 in 203 patients in Japan and Taiwan. A Phase 1 trial, NCT00750295, enrolled 60 patients in the United States.
SBR759 is a phosphate binder designed to lower serum phosphate levels in chronic kidney disease patients on hemodialysis. By binding phosphate in the gastrointestinal tract, it reduces phosphate absorption and helps control hyperphosphatemia.
SBR759 is a distinct investigational phosphate binder developed by Novartis. It is not the same as other marketed phosphate binders, and no alternative names for SBR759 have been reported in clinical trial records.